Torrent Pharmaceuticals Limited (TORNTPHARM) — Financial Results | 13 February 2026(4 announcements)

Torrent Pharmaceuticals reported Q3 FY26 consolidated revenue of ₹3,303 crores (up 18% YoY) and net profit of ₹635 crores (up 26% YoY). Nine-month FY26 revenue reached ₹9,783 crores with net profit of ₹1,774 crores. The company completed acquisition of 48.8% controlling stake in J.B. Chemicals & Pharmaceuticals on January 21, 2026, pending merger approvals. Board approved interim dividend of ₹29 per share (580% on face value). Geographic growth included Brazil 21%, US 19%, and India 14% YoY.

Torrent Pharmaceuticals reported consolidated Q3 FY2026 revenue of ₹3,303 crores (up 18% YoY) with net profit of ₹635 crores (up 26% YoY) and 33% EBITDA margin. Nine-month revenue reached ₹9,783 crores (up 14% YoY) with net profit of ₹1,774 crores (up 26% YoY). The company completed acquisition of 46.39% controlling stake in J.B. Chemicals & Pharmaceuticals on January 21, 2026, strengthening its market position. An interim dividend of ₹29 per share (580%) was approved for March 2026 payment.

Torrent Pharmaceuticals Limited disclosed an audio recording of its analyst conference call for Q3 and nine-month results ended December 31, 2025. The filing is a regulatory notification under SEBI Listing Obligations, providing investors access to management commentary on financial performance. No financial metrics or material updates were detailed in this disclosure.

Torrent Pharmaceuticals reported Q3 FY2025-26 consolidated revenue of ₹3,303 crores, up 18% YoY from ₹2,809 crores. Nine-month revenue reached ₹9,783 crores, growing 14% YoY. India revenue grew 14% to ₹1,798 crores; Brazil surged 27% to ₹371 crores; and Others segment jumped 32% to ₹509 crores. US and Germany markets showed steady growth at 19% and 8% respectively.